A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen
Amgen
Eli Lilly and Company
Immatics Biotechnologies GmbH
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Boehringer Ingelheim
Astellas Pharma Inc
Amgen
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
Astellas Pharma Inc
ModernaTX, Inc.
Astellas Pharma Inc
Bristol-Myers Squibb
Isala
Vividion Therapeutics, Inc.
Erasca, Inc.